Free Trial
OTCMKTS:CLPBY

Coloplast A/S 11/9/2023 Earnings Report

Coloplast A/S logo
$8.85 +0.02 (+0.23%)
As of 10/10/2025 03:59 PM Eastern

Coloplast A/S EPS Results

Actual EPS
$0.08
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Coloplast A/S Revenue Results

Actual Revenue
$909.23 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Coloplast A/S Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Coloplast A/S' next earnings date is estimated for Tuesday, November 4, 2025, based on past reporting schedules.

Conference Call Resources

Coloplast A/S Earnings Headlines

An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
Coloplast A/S - Financial Calendar 2025-26
Coloplast A/S (CLPBY) Capital Markets Day 2025 Transcript
Coloplast A/S (CLPBF) Q3 2025 Earnings Call Transcript
See More Coloplast A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Coloplast A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coloplast A/S and other key companies, straight to your email.

About Coloplast A/S

Coloplast A/S (OTCMKTS:CLPBY) is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste. The continence care segment offers catheters, drainage bags and related supplies for individuals with bladder control issues. The company’s wound and skin care portfolio includes advanced dressings, negative-pressure wound therapy and pressure ulcer prevention products, while its interventional urology line features devices for minimally invasive procedures and diagnostics in urological conditions.

Founded in 1957 by Danish entrepreneur Aage Louis-Hansen, Coloplast began when Louis-Hansen developed the first adhesive ostomy bag to help his wife manage her postoperative care. Since then, the company has grown from a small family operation into a publicly listed corporation on the Copenhagen Stock Exchange, with an American depositary receipt program trading under the symbol CLPBY in the U.S. The company is led by President and CEO Peter Clemmensen, who has overseen continued expansion of R&D and manufacturing capabilities.

Headquartered in Humlebæk, Denmark, Coloplast operates manufacturing and research facilities across Europe and North America, supported by a global sales and distribution network. Its products are available in more than 100 countries, with regional offices and partnerships that ensure local market support and training for healthcare professionals. The company places a strong emphasis on customer proximity and collaborative development to address the evolving needs of patients and clinicians worldwide.

View Coloplast A/S Profile

More Earnings Resources from MarketBeat